Loading organizations...
§ Private Profile · San Francisco, CA, USA
Clinical-stage biotechnology company developing biologics for immunological and inflammatory disorders, using optimized antibodies.
Apogee Therapeutics is a clinical-stage biotechnology company based in Waltham, Massachusetts, that develops novel biologics and optimized monoclonal antibodies for severe inflammatory and immunology disorders. The pre-revenue firm focuses on targeted treatments for conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease, currently advancing its lead candidate APG777 through Phase 2 clinical trials. Operating with a dedicated workforce of 261 employees, the enterprise initially secured $169 million across Series A and B rounds before raising $300 million in a July 2023 initial public offering. In early 2024, the company completed an additional $420 million follow-on public offering backed by institutional investors including Deep Track Capital and RTW Investments. Apogee Therapeutics was founded in 2022 as a spinout from Paragon Therapeutics by co-founder Nimish Shah alongside Fairmount Funds Management and Venrock Healthcare Capital Partners.
Apogee Therapeutics has raised $149.0M across 1 funding round.
Apogee Therapeutics has raised $149.0M in total across 1 funding round.
Apogee Therapeutics has raised $149.0M in total across 1 funding round.
Apogee Therapeutics's investors include Rebecca Luse, RTW Investments.
Apogee Therapeutics has raised $149.0M across 1 funding round. Most recently, it raised $149.0M Series B in December 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 12, 2022 | $149M Series B | Rebecca Luse, RTW Investments | — | Announced |